MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Firm”), a clinical stage pharmaceutical business committed to expanding healthy and balanced life-span, today revealed that the initial client has actually been enlisted in the Business’s Stage 2 medical test of lead prospect MYMD-1, a dental immune regulatory authority drug, as a therapy for delaying aging and also increasing healthy and balanced life-span.
The key endpoint for the Stage 2 double-blind, placebo-controlled scientific test is to accomplish a decrease in the circulating levels of (TNF-α), tumor death factor receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that trigger swelling as well as aid trigger the procedure of aging. The secondary procedures of the test will certainly be the security, tolerability, and pharmacokinetics in this population of patients.
” In a Phase 1 clinical trial of MYMD-1, we demonstrated the drug’s statistically considerable efficiency in reducing degrees of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has approved TNF-α decrease as the key endpoint for our Stage 2 study, which our company believe settings us well for a successful Stage 2 result,” stated Chris Chapman, M.D., President, Director and also Chief Medical Officer of MyMD. “The initiation of individual enrollment in this research study advances our objective to reduce the aging procedure, stop loss of muscle tissue in aging, limitation frailty, and also extend healthy life expectancy.”
MyMD has actually stated that there are no FDA-approved medicines for treating aging conditions as well as expanding healthy lifespan humans, a market expected to be a minimum of $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most prescribed medications by earnings, a global market of approximately $40 billion per year,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would certainly boost life span by one year deserves $38 trillion and by ten years deserves $367 trillion.
Along with aging, MYMD-1’s distinctive activity in managing the body immune system as well as dealing with chronic inflammation is being established for the treatment of autoimmune illness, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetic issues, and also inflammatory bowel illness.
” We intend to begin creating procedures for a Stage 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing frequency of rheumatoid joint inflammation and also various other autoimmune as well as inflammatory diseases are driving demand for TNF inhibitors like MYMD-1, and our team believe our by mouth provided medicine with very reduced toxicity would be disruptive to the $60 billion market for RA if approved by the FDA for this indication.”
Rheumatoid joint inflammation influences around 40 million people globally.4.
Originally developed for autoimmune conditions, MYMD-1’s primary function is to slow the aging procedure, prevent sarcopenia and frailty, and extend healthy life expectancy. Because it can go across the blood-brain barrier and also get to the main nerve system (CNS), MYMD-1 is also placed to be a feasible therapy for brain-related problems. Its mechanism of activity and also efficiency in conditions consisting of multiple sclerosis (MS) and thyroiditis have been researched with partnerships with a number of academic institutions. MYMD-1 is likewise revealing guarantee in pre-clinical researches as a potential treatment for blog post- COVID-19 issues and also as an anti-fibrotic as well as anti-proliferation restorative.
MYMD-1 has revealed efficiency in pre-clinical research studies in regulating the immune system by executing as a discerning prevention of lump death factor-alpha (TNF-α), a vehicle driver of persistent swelling. Unlike other treatments, MYMD-1 has been received these pre-clinical researches to precisely obstruct TNF-α when it comes to be overactivated in autoimmune diseases and also cytokine storms, yet not block it from doing its normal job of being an initial -responder to any type of routine type of moderate infection. MYMD-1’s simplicity of dental dosing is one more differentiator compared to currently readily available TNF-α blockers, every one of which need distribution by shot or infusion. No accepted TNF inhibitor has ever been dosed orally. On top of that, the medicine is not immunosuppressive and has not been shown to cause the significant negative effects common with conventional treatments that deal with swelling.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical business devoted to extending healthy lifespan, is focused on developing two unique therapeutic platforms that treat the sources of illness as opposed to just resolving the symptoms. MYMD-1 is a medicine platform based on a professional stage tiny particle that manages the immune system to control TNF-α, which drives persistent swelling, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, boost long life, and treat autoimmune diseases and also COVID-19- associated anxiety. The Business’s 2nd medication platform, Supera-CBD, is being created to deal with chronic pain, dependency as well as epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and also is being created to deal with as well as improve upon the quickly expanding CBD market, that includes both FDA accepted drugs and CBD products not currently managed as drugs. To find out more, browse through www.mymd.com.